{
    "root": "05d92b25-043c-4264-8910-c717cd316d50",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Blisovi 24 Fe",
    "value": "20250508",
    "ingredients": [],
    "indications": "blisovi™ 24 fe indicated women prevent pregnancy [ ( 14 ) ] . efficacy blisovi 24 fe women body mass index ( bmi ) > 35 kg/m2 evaluated .",
    "contraindications": "take one tablet mouth time every day 28 days ( 2.1 ) take tablets order directed blister pack ( 2.1 ) blisovi 24 fe may administered without regard meals ( 12.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "blisovi 24 fe contraindicated females known develop following conditions : high risk arterial venous thrombotic diseases . examples include women known : smoke , age 35 [ boxed warning ( 5.1 ) ] deep vein thrombosis pulmonary embolism , past [ ( 5.1 ) ] inherited acquired hypercoagulopathies [ ( 5.1 ) ] cerebrovascular disease [ ( 5.1 ) ] coronary artery disease [ ( 5.1 ) ] thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] uncontrolled hypertension [ ( 5.4 ) ] diabetes mellitus vascular disease [ ( 5.6 ) ] headaches focal neurological symptoms migraine headaches aura [ ( 5.7 ) ] ■ women age 35 migraine headaches [ ( 5.7 ) ] liver tumors , benign malignant , liver disease [ ( 5.2 ) ] undiagnosed abnormal uterine bleeding [ ( 5.8 ) ] current diagnosis , history , breast cancer , may hormone sensitive [ ( 5.11 ) ] hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations [ ( 5.3 ) ]",
    "indications_original": "Blisovi™ 24 Fe is indicated for use by women to prevent pregnancy [see CLINICAL STUDIES (14)].\n                  \n                  The efficacy of Blisovi 24 Fe in women with a body mass index (BMI) of > 35 kg/m2 has not been evaluated.",
    "contraindications_original": "Take one tablet by mouth at the same time every day for 28 days ( 2.1 ) Take tablets in the order directed on the blister pack ( 2.1 ) Blisovi 24 Fe may be administered without regard to meals ( 12.3 )",
    "adverseReactions_original": "Blisovi 24 Fe is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:\n                           Smoke, if over age 35 [see BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have deep vein thrombosis or pulmonary embolism, now or in the past [see WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have inherited or acquired hypercoagulopathies [see WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have cerebrovascular disease [see WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have coronary artery disease [see WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see WARNINGS AND PRECAUTIONS (5.1)]\n                           \n                           Have uncontrolled hypertension [see WARNINGS AND PRECAUTIONS (5.4)]\n                           \n                           Have diabetes mellitus with vascular disease [see WARNINGS AND PRECAUTIONS (5.6)]\n                           \n                           Have headaches with focal neurological symptoms or have migraine headaches with aura [see WARNINGS AND PRECAUTIONS (5.7)]\n                           \n                        \n                     \n                  \n                  ■    Women over age 35 with any migraine headaches [see WARNINGS AND PRECAUTIONS (5.7)]\n                  \n                  \n                     Liver tumors, benign or malignant, or liver disease [see WARNINGS AND PRECAUTIONS (5.2)]\n                     \n                     Undiagnosed abnormal uterine bleeding [see WARNINGS AND PRECAUTIONS (5.8)]\n                     \n                     Current diagnosis of, or history of, breast cancer, which may be hormone sensitive [see WARNINGS AND PRECAUTIONS (5.11)]\n                     \n                     Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see WARNINGS AND PRECAUTIONS (5.3)]"
}